clip

CLIP (86-100) is an amino acids 86 to 100 fragment of the class II-associated invariant chain peptide called CLIP. The major histocompatibility complex class II molecule displays peptide fragments of foreign proteins to trigger an immune response. Before foreign peptides bind, a place-holding CLIP peptide is removed by the molecule DM, which increases the dissociation rate of CLIP from class II.

CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen-binding groove.

CLIP 86-100 acetate(648881-58-7 free base) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide called CLIP. The major histocompatibility complex class II molecule displays peptide fragments of foreign proteins to trigger a defensive reaction from the immune system. Before insertion of the foreign peptides into the binding groove, a place-holding peptide CLIP is removed. CLIP 86-100 acetate(648881-58-7 free base) is accomplished by the molecule DM, which is shown to increase the dissociation rate of a CLIP peptide from class II.

Adrenocorticotropic Hormone (ACTH) (18-39), human TFA (CLIP human TFA) is a corticotropin-like intermediate lobe peptide produced in the melanotrophs of the pituitary's intermediate lobe.

1. Ecliptasaponin A (Echinocystic acid-3-o-glucoside) has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition.

Oxyclipine is a bioactive chemical.

Ecliptasaponin D is a natural product for research related to life sciences. The catalog number is T3S0687 and the CAS number is 206756-04-9.

ERK-CLIPTAC is a PROTAC (PROteolysis TArgeting Chimera) molecule designed to induce the degradation of Extracellular signal-Regulated Kinase (ERK) [1].

Ecliptasaponin A (Standard) is a reference standard for research and analysis in studies involving Ecliptasaponin A. 1. Ecliptasaponin A (Echinocystic acid-3-o-glucoside) has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition.

Ecliptasaponin B is a natural product that can be used in related research in the field of life sciences. Its product number is TN8610.

Oleic acid (Glycon Wo) is a natural product, a common monounsaturated fatty acid found in a variety of animal and vegetable fats and oils. Palmitic acid is a Na+/K+ ATPase activator.

Carbendazim (Mercarzole) is a broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.

Cetilistat (ATL-962) is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

Glymidine sodium is a sulfonamide hypoglycemic agent which stimulates insulin secretion.

DOTAP chloride (1, 2-dioleoyl-3-trimethylammonium-propane chloride) is an efficient cationic lipid, and its target is mainly the negatively charged components on the cell membrane. DOTAP chloride binds to negatively charged nucleic acids (such as DNA and RNA) by electrostatic interaction to form complexes, thereby achieving the delivery of nucleic acids.

Pancreatic lipase-IN-1 (compound 8) is an inhibitor of pancreatic lipase with a Ki value of 1.288 μM.

Pancreatic lipase-IN-2 (compound 7r) is a potent inhibitor of pancreatic lipase (PL), with an IC50 value of 2.67 μM, and exhibits anti-obesity effects.

Wedelolactone (IKK Inhibitor II) inhibits NF-κB-mediated gene transcription in cells by blocking the phosphorylation and degradation of IκBα.

3,4,5-Trihydroxycinnamic acid decyl ester, an effective inhibitor of lipid absorption and accumulation, exhibits anti-obesity properties and acts as a pancreatic lipase inhibitor, with an EC50 of approximately 0.9 μM.

1. Gypsogenin-3-O-glucuronide (Methyl gypsogenin 3-O-beta-D-glucuronopy) shows inhibitory activity toward pancreatic lipase with IC5 value of .29 mM, and the free carboxylic acid groups in position 28 within its chemical structures are required for enhancement of pancreatic lipase inhibition.

Pancreatic lipase/Carboxylesterase 1-IN-1 (Compound 39) is a potent dual inhibitor of pancreatic lipase (PL) with an IC50 of 2.13 μM and human carboxylesterase 1A (hCES1A) with an IC50 of 0.055 μM.

hPL-IN-1 is a potent reversible pancreatic lipase (PL) inhibitor (IC50=1.86 μM) that can be used to study obesity-related diseases.

hPL-IN-2 is a potent, reversible and non-competitive inhibitor of Pancreatic lipase (IC50: 1.63 μM) that can be used to investigate obesity-related diseases.

Neladalkib (NVL-655) is a selective and brain-permeable ALK inhibitor with antitumor activity that inhibits a variety of ALK-mutant oncoproteins, and may be useful in the study of non-small cell cancers.